Compare CDIO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | JAGX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 9 | 49 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.0M |
| IPO Year | N/A | 2014 |
| Metric | CDIO | JAGX |
|---|---|---|
| Price | $2.60 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 6.6M | 486.0K |
| Earning Date | 03-13-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | $171,906.75 | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $0.18 | $0.20 |
| 52 Week High | $7.91 | $15.48 |
| Indicator | CDIO | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 34.10 |
| Support Level | $1.26 | N/A |
| Resistance Level | $4.24 | $0.69 |
| Average True Range (ATR) | 0.82 | 0.08 |
| MACD | -0.39 | -0.01 |
| Stochastic Oscillator | 9.18 | 1.08 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.